Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(9 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Indiana University, Indianapolis, Indiana

University of Kansas Medical Center, Kansas City, Kansas

Washington University in St. Louis, St Louis, Missouri

Cooper University Health System, Camden, New Jersey

The Ohio State University, Columbus, Ohio

Rhode Island Hospital, Providence, Rhode Island

The Miriam Hospital, Providence, Rhode Island

University of Texas Health Science Center at San Antonio, San Antonio, Texas